Matthew Maurer

4.4k total citations
54 papers, 1.4k citations indexed

About

Matthew Maurer is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Matthew Maurer has authored 54 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 22 papers in Molecular Biology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Matthew Maurer's work include PI3K/AKT/mTOR signaling in cancer (8 papers), Cancer Genomics and Diagnostics (6 papers) and Advanced Breast Cancer Therapies (6 papers). Matthew Maurer is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (8 papers), Cancer Genomics and Diagnostics (6 papers) and Advanced Breast Cancer Therapies (6 papers). Matthew Maurer collaborates with scholars based in United States, Australia and Canada. Matthew Maurer's co-authors include Kevin Kalinsky, Dawn L. Hershman, Katherine D. Crew, Heather Greenlee, Hanina Hibshoosh, James J. Manfredi, Selvon St. Clair, Benjamin D. Hopkins, Ramon Parsons and Megan Keniry and has published in prestigious journals such as Science, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Matthew Maurer

52 papers receiving 1.4k citations

Peers

Countries citing papers authored by Matthew Maurer

Since Specialization

Citations

This map shows the geographic impact of Matthew Maurer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Maurer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Maurer more than expected).

Fields of papers citing papers by Matthew Maurer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Maurer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Maurer. The network helps show where Matthew Maurer may publish in the future.

Co-authorship network of co-authors of Matthew Maurer

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Maurer. A scholar is included among the top collaborators of Matthew Maurer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Maurer. Matthew Maurer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment 2025 ·Integrative Cancer Therapies ·Heather Greenlee, Katherine D. Crew, Matthew Maurer, Kevin Kalinsky, Serge Cremers, Ali Naini, Wei Yann Tsai, Zaixing Shi, Frances Brogan, Dawn L. Hershman	0
2	First-in-human mRNA CAR therapy: Correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors. 2025 ·Journal of Clinical Oncology ·Charlotte Lemech, Rasha Cosman, (unknown), Ganessan Kichenadasse, Gary Richardson, Adnan Nagrial, Christina T. Teng, Jia Liu, Anthony M. Joshua, (unknown), (unknown), Kate Harvey, Hanyun Zhang, (unknown), Nicholas J. C. King, (unknown), Michele Cioffi, Matthew Maurer, Daniel R. Getts, Alexander Swarbrick	1
3	One health genomic surveillance and response to a university-based outbreak of the SARS-CoV-2 Delta AY.25 lineage, Arizona, 2021 2022 ·PLoS ONE ·Hayley D. Yaglom, Matthew Maurer, (unknown), (unknown), (unknown), Jolene R. Bowers, (unknown), (unknown), (unknown), (unknown), (unknown), Efrem S. Lim, (unknown), Crystal M. Hepp, David M. Engelthaler	4
4	Applying Genomic Epidemiology to Characterize a COVID-19 Outbreak in a Developmentally Disabled Adult Group Home Setting, Arizona 2021 ·Frontiers in Public Health ·Hayley D. Yaglom, (unknown), (unknown), (unknown), (unknown), Darrin Lemmer, Megan Folkerts, (unknown), Matthew Maurer, Jolene R. Bowers, David M. Engelthaler	2
5	Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer 2019 ·Clinical Breast Cancer ·Kathleen Fenn, Matthew Maurer, Shing M. Lee, Katherine D. Crew, Meghna S. Trivedi, Melissa Accordino, Dawn L. Hershman, Kevin Kalinsky	26
6	Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy 2019 ·Clinical Breast Cancer ·(unknown), Maika Onishi, Danielle Awad, Donna Buono, Matthew Maurer, Katherine D. Crew, Elizabeth Shane, Dawn L. Hershman, Kevin Kalinsky	6
7	Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214 2019 ·European Urology ·Bernard Escudier, Robert J. Motzer, Nizar M. Tannir, Camillo Porta, Yoshihiko Tomita, Matthew Maurer, M. Brent McHenry, Brian I. Rini	53
8	Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial 2018 ·Clinical & Translational Oncology ·Kevin Kalinsky, Joseph A. Sparano, Xiaobo Zhong, Eleni Andreopoulou, Bret Taback, Lisa Wiechmann, Sheldon Feldman, Preya Ananthakrishnan, Aqeel Ahmad, Serge Cremers, Anthony Sireci, Justin R. Cross, Douglas K. Marks, Prabhjot S. Mundi, Eileen P. Connolly, Katherine D. Crew, Matthew Maurer, Hanina Hibshoosh, Stephen A. Lee, (unknown)	19
9	Proteomic modulation in breast tumors after metformin exposure: results from a “window of opportunity” trial 2016 ·Clinical & Translational Oncology ·Kevin Kalinsky, Ting Zheng, Hanina Hibshoosh, Xing Du, Prabhjot S. Mundi, Jie Yang, (unknown), Sheldon Feldman, Bret Taback, Eileen P. Connolly, Katherine D. Crew, Matthew Maurer, Dawn L. Hershman	7
10	¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors 2015 ·Journal of the Academy of Nutrition and Dietetics ·Heather Greenlee, (unknown), (unknown), (unknown), Isobel R. Contento, Wahida Karmally, John M. Richardson, Emerson A. Lim, Wei‐Yann Tsai, Katherine D. Crew, Matthew Maurer, Kevin Kalinsky, Dawn L. Hershman	58
11	¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors 2015 ·Journal of the Academy of Nutrition and Dietetics ·Heather Greenlee, (unknown), (unknown), (unknown), Isobel R. Contento, Wahida Karmally, John M. Richardson, Emerson A. Lim, Wei‐Yann Tsai, Katherine D. Crew, Matthew Maurer, Kevin Kalinsky, Dawn L. Hershman	20
12	Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer 2015 ·PubMed ·(unknown), Tong Xiao, (unknown), Mary Beth Terry, Matthew Maurer, Kevin Kalinsky, Sheldon Feldman, Lois Brafman, (unknown), (unknown)	26
13	Breast Cancer Prognostic Biomarker Using Attractor Metagenes and the FGD3–SUSD3 Metagene 2014 ·Cancer Epidemiology Biomarkers & Prevention ·Tai-Hsien Ou Yang, Wei‐Yi Cheng, Tian Zheng, Matthew Maurer, Dimitris Anastassiou	17
14	Increased Expression of Tumor Proliferation Genes in Hispanic Women with Early-Stage Breast Cancer 2014 ·Cancer Investigation ·Kevin Kalinsky, Emerson A. Lim, Eleni Andreopoulou, Avni M. Desai, Zhezhen Jin, Yifan Tu, Hanina Hibshoosh, Antai Wang, Heather Greenlee, Katherine D. Crew, Matthew Maurer, Joseph A. Sparano, Dawn L. Hershman	10
15	Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors 2013 ·Breast Cancer Research and Treatment ·Dawn L. Hershman, Heather Greenlee, Danielle Awad, Kevin Kalinsky, Matthew Maurer, Grace Kranwinkel, Lois Brafman, (unknown), Wei‐Yann Tsai, Alfred I. Neugut, Katherine D. Crew	98
16	Abstract 28: Phase I trial of combined temsirolimus, erlotinib, and cisplatin in advanced solid tumors. 2013 ·Cancer Research ·Matthew Maurer, Kevin Kalinsky, Katherine D. Crew, (unknown), Julia Forman, Ying-Ka Ingar Lau, Ramon Parsons, Dawn L. Hershman	3
17	Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer 2012 ·Supportive Care in Cancer ·Heather Greenlee, Katherine D. Crew, Theresa Shao, Grace Kranwinkel, Kevin Kalinsky, Matthew Maurer, Lois Brafman, Beverly J. Insel, Wei Yann Tsai, Dawn L. Hershman	37
18	Activation of the PI3K Pathway in Cancer Through Inhibition of PTEN by Exchange Factor P-REX2a 2009 ·Science ·Barry Fine, Cindy Hodakoski, Susan Koujak, Tao Su, Lao H. Saal, Matthew Maurer, Benjamin D. Hopkins, Megan Keniry, Maria Luisa Sulis, Sarah M. Mense, Hanina Hibshoosh, Ramon Parsons	182
19	Electrophoretic Mobility Shift Analysis of the DNA Binding of Tumor Suppressor Gene Products 2003 ·Humana Press eBooks ·Edward C. Thornborrow, Matthew Maurer, James J. Manfredi	2
20	Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53 1998 ·Genes & Development ·(unknown), Selvon St. Clair, Matthew Maurer, (unknown), James J. Manfredi	102

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact